NCT06582914 Lynch Syndrome Integrative Epidemiology and Genetics
| NCT ID | NCT06582914 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Lynch Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2054-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2024-10-01 with a primary completion date of 2054-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The vision of the "Lynch syndrome INtegrative Epidemiology And GEnetics" (LINEAGE) Consortium is to collaboratively improve the lives and longevity of individuals and families with Lynch syndrome. The mission of the LINEAGE Consortium is to collaboratively improve Lynch syndrome care through high-quality research. This consortium will provide intellectual and infrastructure support to facilitate development of research questions, collection of standardized data and biospecimens, support of grant applications, and generation of collaborative manuscripts. Our aims are to: I. Establish a prospective cohort of individuals with Lynch syndrome II. Collect standardized longitudinal clinical and biosample data to elucidate Lynch Syndrome epidemiology and gene-host interactions III. Promote intervention trials to improve cancer prevention and early detection in Lynch Syndrome
Eligibility Criteria
Inclusion Criteria: * • Adults age over 18 years * Eligible patients must have at least one variant of uncertain significance (VUS), pathogenic or likely pathogenic variant (PV/LPV) in MLH1, MSH2, MSH6, PMS2, or EPCAM, which will be confirmed by genetic testing results (obtained as part of routine care) and a review of the variant in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/). * Individuals who are an obligate carrier of a LS PV/LPV that is confirmed in the family. Exclusion Criteria: * Age under 18
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06582914 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lynch Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06582914 currently recruiting?
Yes, NCT06582914 is actively recruiting participants. Contact the research team at swati.patel@cuanschutz.edu for enrollment information.
Where is the NCT06582914 trial being conducted?
This trial is being conducted at Aurora, United States, Chicago, United States.
Who is sponsoring the NCT06582914 clinical trial?
NCT06582914 is sponsored by University of Colorado, Denver. The trial plans to enroll 5,000 participants.